Daniel Nicholas Ricotta, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hospitalists | 5 | 2021 | 292 | 2.080 |
Why?
|
| Legal Guardians | 1 | 2018 | 54 | 0.670 |
Why?
|
| Education, Medical | 2 | 2021 | 1683 | 0.660 |
Why?
|
| Teaching Rounds | 1 | 2020 | 223 | 0.610 |
Why?
|
| Internship and Residency | 4 | 2020 | 5556 | 0.590 |
Why?
|
| Burnout, Professional | 3 | 2020 | 628 | 0.580 |
Why?
|
| Hospital Charges | 1 | 2018 | 362 | 0.570 |
Why?
|
| Leadership | 2 | 2021 | 1325 | 0.540 |
Why?
|
| Clinical Competence | 7 | 2021 | 4615 | 0.530 |
Why?
|
| Education, Medical, Undergraduate | 2 | 2021 | 988 | 0.530 |
Why?
|
| Self Efficacy | 1 | 2018 | 629 | 0.500 |
Why?
|
| Medicine | 1 | 2021 | 851 | 0.500 |
Why?
|
| Physicians | 3 | 2020 | 4292 | 0.500 |
Why?
|
| Patient Care | 1 | 2019 | 610 | 0.480 |
Why?
|
| Learning | 3 | 2021 | 1596 | 0.480 |
Why?
|
| Intelligence | 1 | 2018 | 895 | 0.470 |
Why?
|
| Referral and Consultation | 3 | 2021 | 3436 | 0.450 |
Why?
|
| Apolipoprotein B-100 | 1 | 2012 | 171 | 0.430 |
Why?
|
| Students, Medical | 2 | 2021 | 1740 | 0.420 |
Why?
|
| Inpatients | 2 | 2021 | 2207 | 0.400 |
Why?
|
| Teaching | 4 | 2021 | 1185 | 0.400 |
Why?
|
| Internal Medicine | 1 | 2017 | 1007 | 0.390 |
Why?
|
| Oligonucleotides | 1 | 2012 | 609 | 0.340 |
Why?
|
| Medical Oncology | 1 | 2019 | 2098 | 0.330 |
Why?
|
| Hypercholesterolemia | 1 | 2012 | 1167 | 0.270 |
Why?
|
| Curriculum | 4 | 2021 | 3329 | 0.270 |
Why?
|
| Anticholesteremic Agents | 1 | 2012 | 964 | 0.260 |
Why?
|
| Length of Stay | 1 | 2018 | 6257 | 0.260 |
Why?
|
| Delivery of Health Care | 1 | 2019 | 4810 | 0.210 |
Why?
|
| Faculty, Medical | 3 | 2021 | 1156 | 0.210 |
Why?
|
| Jurisprudence | 1 | 2019 | 119 | 0.180 |
Why?
|
| Pulmonary Medicine | 2 | 2018 | 215 | 0.180 |
Why?
|
| Blood Sedimentation | 1 | 2019 | 237 | 0.170 |
Why?
|
| Kinesics | 1 | 2017 | 12 | 0.170 |
Why?
|
| Nonverbal Communication | 1 | 2017 | 64 | 0.160 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2012 | 3097 | 0.160 |
Why?
|
| Psychological Theory | 1 | 2018 | 170 | 0.160 |
Why?
|
| Education, Medical, Graduate | 2 | 2019 | 2176 | 0.150 |
Why?
|
| Feedback | 1 | 2020 | 747 | 0.150 |
Why?
|
| Observation | 1 | 2017 | 310 | 0.150 |
Why?
|
| Humans | 25 | 2022 | 708843 | 0.140 |
Why?
|
| Giant Cell Arteritis | 1 | 2019 | 255 | 0.140 |
Why?
|
| Metformin | 1 | 2022 | 800 | 0.140 |
Why?
|
| Peer Group | 1 | 2020 | 633 | 0.130 |
Why?
|
| Communication | 2 | 2019 | 3455 | 0.130 |
Why?
|
| Critical Care | 2 | 2018 | 2473 | 0.130 |
Why?
|
| Personal Satisfaction | 1 | 2018 | 596 | 0.120 |
Why?
|
| Evidence-Based Practice | 1 | 2018 | 503 | 0.120 |
Why?
|
| Interdisciplinary Communication | 1 | 2019 | 980 | 0.120 |
Why?
|
| Informed Consent | 1 | 2018 | 959 | 0.110 |
Why?
|
| Anti-Infective Agents | 1 | 2018 | 927 | 0.100 |
Why?
|
| Educational Measurement | 1 | 2018 | 1271 | 0.100 |
Why?
|
| Catheterization, Central Venous | 1 | 2015 | 511 | 0.100 |
Why?
|
| Waldenstrom Macroglobulinemia | 1 | 2019 | 999 | 0.100 |
Why?
|
| Administration, Oral | 1 | 2018 | 3944 | 0.100 |
Why?
|
| Administration, Cutaneous | 1 | 2012 | 696 | 0.100 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2012 | 434 | 0.090 |
Why?
|
| Bacterial Infections | 1 | 2018 | 1423 | 0.090 |
Why?
|
| Motivation | 1 | 2018 | 1868 | 0.090 |
Why?
|
| Societies, Medical | 1 | 2020 | 3776 | 0.080 |
Why?
|
| Cardiovascular Diseases | 1 | 2012 | 14075 | 0.080 |
Why?
|
| Patient Discharge | 1 | 2018 | 2980 | 0.070 |
Why?
|
| Physician-Patient Relations | 1 | 2019 | 3316 | 0.070 |
Why?
|
| Drug Administration Schedule | 1 | 2012 | 5045 | 0.060 |
Why?
|
| Reproducibility of Results | 1 | 2020 | 19423 | 0.050 |
Why?
|
| Prospective Studies | 2 | 2021 | 50597 | 0.040 |
Why?
|
| Credentialing | 1 | 2019 | 131 | 0.040 |
Why?
|
| Child, Preschool | 1 | 2021 | 41081 | 0.040 |
Why?
|
| Hospitalization | 1 | 2018 | 9644 | 0.040 |
Why?
|
| Patient Simulation | 1 | 2018 | 307 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2012 | 8024 | 0.040 |
Why?
|
| Catheter-Related Infections | 1 | 2018 | 239 | 0.030 |
Why?
|
| Immunoglobulin M | 1 | 2019 | 1527 | 0.030 |
Why?
|
| Manikins | 1 | 2015 | 234 | 0.030 |
Why?
|
| United States | 2 | 2019 | 67165 | 0.030 |
Why?
|
| Models, Educational | 1 | 2015 | 396 | 0.030 |
Why?
|
| Headache | 1 | 2019 | 1109 | 0.030 |
Why?
|
| Vision Disorders | 1 | 2019 | 1038 | 0.030 |
Why?
|
| Models, Anatomic | 1 | 2015 | 684 | 0.030 |
Why?
|
| Retrospective Studies | 1 | 2018 | 71483 | 0.020 |
Why?
|
| Hypoglycemic Agents | 1 | 2022 | 2734 | 0.020 |
Why?
|
| Hospitals | 1 | 2022 | 3290 | 0.020 |
Why?
|
| Cross Infection | 1 | 2018 | 1412 | 0.020 |
Why?
|
| C-Reactive Protein | 1 | 2019 | 3696 | 0.020 |
Why?
|
| Adult | 1 | 2021 | 211041 | 0.020 |
Why?
|
| Biopsy | 1 | 2019 | 6766 | 0.020 |
Why?
|
| Fellowships and Scholarships | 1 | 2015 | 978 | 0.020 |
Why?
|
| Middle Aged | 1 | 2018 | 213752 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2019 | 13274 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2019 | 15252 | 0.010 |
Why?
|
| Female | 2 | 2019 | 375205 | 0.010 |
Why?
|
| Male | 1 | 2018 | 349524 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2021 | 39292 | 0.010 |
Why?
|
| Aged | 1 | 2019 | 161488 | 0.000 |
Why?
|